Akebia Therapeutics Inc’s recent filing unveils that its CEO and President Butler John P. unloaded Company’s shares for reported $84928.0 on Mar 03 ’25. In the deal valued at $1.83 per share,46,409 shares were sold. As a result of this transaction, Butler John P. now holds 2,557,921 shares worth roughly $7.16 million.
Then, Burke Steven Keith sold 7,144 shares, generating $13,074 in total proceeds. Upon selling the shares at $1.83, the SVP, Chief Medical Officer now owns 809,090 shares.
Before that, Burke Steven Keith bought 7,144 shares. Akebia Therapeutics Inc shares valued at $13,086 were divested by the Officer at a price of $1.83 per share.
Leerink Partners initiated its Akebia Therapeutics Inc [AKBA] rating to an Outperform in a research note published on April 28, 2025; the price target was $7. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in early April with a ‘”a Buy”‘ rating. H.C. Wainwright revised its rating on August 28, 2023. It rated AKBA as “a Buy” which previously was an “a Neutral”.
Price Performance Review of AKBA
On Monday, Akebia Therapeutics Inc [NASDAQ:AKBA] saw its stock jump 7.28% to $2.80. Over the last five days, the stock has gained 15.23%. Akebia Therapeutics Inc shares have risen nearly 47.37% since the year began. Nevertheless, the stocks have risen 137.29% over the past one year.
How much short interest is there in Akebia Therapeutics Inc?
A steep rise in short interest was recorded in Akebia Therapeutics Inc stocks on 2025-04-30, growing by 0.41 million shares to a total of 17.77 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 17.36 million shares. There was a rise of 2.32%, which implies that there is a positive sentiment for the stock.
